said late Thursday that they have agreed to market an HIV pill in Canada.
Atripla is a once-daily, single-tablet regimen for the treatment of HIV-1 infection in adults that combines efavirenz, emtricitabine and tenofovir disoproxil fumarate. The two companies seek to commercialize the pill in Canada, subject to approval of the product by Health Canada.
The tablet, which according to the companies, won U.S. Food & Drug Administration approval in July 2006, is intended as a stand-alone therapy or in combination with other antiretrovirals.
Gilead CEO John Martin said in a statement that the companies are "pleased to have finalized our agreement for Canada, and are working expeditiously to complete the regulatory filing for Atripla with Health Canada. ... We working to make it available to all patients who need it as quickly as possible."
Earlier in September, Bristol-Myers
removed Peter Dolan as chief executive, a day after an independent monitor recommended he be fired. He was replaced temporarily with James Cornelius, the former chairman of Guidant.
Shares of Bristol-Myers closed the regular session off 15 cents to $24.85; shares of biopharmaceutical company Gilead gained $1.30 to $68.63.